Align Technology, Inc. ALGN

NASDAQ · Healthcare · Medical - Devices

$155.17

Close on Fri, 20 Nov 2026 · market value $10.9B

What the price is betting on

Priced for a lot to go right

At $155, the price assumes revenue grows about 8.8% a year for five years, from $4.2B to about $6B by FY2030. That is about four times what analysts expect for the next two years and about three times the company's own last three years.

The price assumes8.8%
Analysts, next two years2.5%
Last 3 years2.7%

Revenue growth a year. The price figure comes from a reverse DCF at a 11% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than ALGN? Check up to 5 of your stocks at once, free, no account.

0$2B$4B$6B$4.2B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$111

Base

$121

Bull

$133

Today $155

  • Bear $111. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $121. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $133. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$4.2B$4.1B, on the path
  3. FY2027$4.6B$4.2B, below the path
  4. FY2028$5B$4.4B, below the path
  5. FY2029$5.5B$4.7B, below the path
  6. FY2030$6BThe full bet

Each year's revenue at 8.8% growth from $4.2B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Devices · listed on NASDAQ

Revenue, FY2025
$4B
Growth, 3 years a year
2.7%
Cash margin
12%
Net cash
$980M
Shares, 3-year change
−7.4%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.